Skip to content

Arpeggio Biosciences

4 viewers · 30d

Total raised

$24.1M

2 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $20.0M
ROUNDS
2
INVESTORS
14
FOUNDED
N/A
HQ
Boulder, CO
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
4

AI overview

Updated

Arpeggio Biosciences, Inc. is a biotech innovator specializing in advanced drug discovery solutions through the integration of transcriptomics and artificial intelligence. By leveraging cutting-edge technology and vast datasets, the company is poised to revolutionize the identification of effective treatments for complex diseases.

What sets it apart

Arpeggio's GRETA™ platform offers a unique combination of machine learning and comprehensive biological assays that facilitate a deeper understanding of complex cellular networks, setting the company apart in the pharmaceutical landscape.

Funding history

2 rounds
EquityNov 12, 2025
Form D
+$20.0M$24.1M total
Equity+2Mar 19, 2025
Form D
+$4.0M$4.0M total

Products

1 tracked

GRETA™ Platform

Drug Discovery Technology

The GRETA™ platform represents a cutting-edge technological frontier in drug discovery, merging proprietary biological assays with advanced machine learning algorithms. This synergy enables rapid, high-resolution analyses of cellular changes in response to drug treatments, pushing the boundaries of conventional drug development practices.

  • Comprehensive analysis of cellular dynamics
  • Proprietary chemotranscriptomics database
  • Predictive capabilities for drug toxicity
  • Rapid and cost-effective sequencing of mRNA

Links

WebsiteSEC EDGAR filings